Avantor (NYSE:AVTR) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Avantor (NYSE:AVTR) from a buy rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Morgan Stanley upped their price objective on Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Wells Fargo & Company raised their target price on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Wolfe Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Citigroup boosted their price target on Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Finally, UBS Group began coverage on Avantor in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $16.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.47.

Avantor Stock Performance

Shares of NYSE AVTR opened at $15.81 on Friday. The firm has a 50 day moving average of $14.52 and a 200 day moving average of $10.92. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of -18.83, a price-to-earnings-growth ratio of 11.58 and a beta of 0.94. Avantor has a 12-month low of $7.26 and a 12-month high of $16.05.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm’s revenue was up .5% on a year-over-year basis. During the same period in the prior year, the company earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts anticipate that Avantor will post 0.81 earnings per share for the current year.

Institutional Trading of Avantor

Several institutional investors and hedge funds have recently modified their holdings of the company. Parallel Advisors LLC boosted its holdings in Avantor by 21.4% in the 1st quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock worth $66,000 after buying an additional 1,491 shares during the period. Kera Capital Partners Inc. increased its stake in Avantor by 8.6% in the 4th quarter. Kera Capital Partners Inc. now owns 24,992 shares of the company’s stock worth $273,000 after buying an additional 1,971 shares in the last quarter. Pictet Asset Management Holding SA raised its holdings in Avantor by 2.2% during the first quarter. Pictet Asset Management Holding SA now owns 106,835 shares of the company’s stock valued at $838,000 after acquiring an additional 2,274 shares during the period. Hsbc Holdings PLC raised its holdings in Avantor by 8.0% during the second quarter. Hsbc Holdings PLC now owns 33,534 shares of the company’s stock valued at $332,000 after acquiring an additional 2,497 shares during the period. Finally, HighTower Advisors LLC lifted its position in shares of Avantor by 3.4% in the second quarter. HighTower Advisors LLC now owns 85,072 shares of the company’s stock valued at $842,000 after acquiring an additional 2,787 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.